tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NervGen Pharma Reports Breakthrough in Spinal Cord Injury Treatment
Company AnnouncementsNervGen Pharma Reports Breakthrough in Spinal Cord Injury Treatment
13d ago
NervGen Pharma’s NVG-291-R Shows Promising Preclinical Results in Nerve Repair
PremiumCompany Announcements
NervGen Pharma’s NVG-291-R Shows Promising Preclinical Results in Nerve Repair
18d ago
NervGen Pharma Announces Leadership Change Amid Positive Trial Results
PremiumCompany Announcements
NervGen Pharma Announces Leadership Change Amid Positive Trial Results
2M ago
NervGen Pharma Updates on Equity Program and Stock Options
PremiumCompany Announcements
NervGen Pharma Updates on Equity Program and Stock Options
2M ago
NervGen Pharma Strengthens Leadership Amid Positive Trial Results
PremiumCompany Announcements
NervGen Pharma Strengthens Leadership Amid Positive Trial Results
2M ago
NervGen Pharma Announces Leadership Transition Amid NVG-291 Advancements
PremiumCompany AnnouncementsNervGen Pharma Announces Leadership Transition Amid NVG-291 Advancements
2M ago
NervGen Pharma Appoints Dr. Randall Kaye as Chief Medical Advisor
Premium
Company Announcements
NervGen Pharma Appoints Dr. Randall Kaye as Chief Medical Advisor
3M ago
NervGen Pharma price target raised to C$6 from C$4.50 at Raymond James
Premium
The Fly
NervGen Pharma price target raised to C$6 from C$4.50 at Raymond James
3M ago
NervGen Pharma price target raised to C$5 from C$4.50 at Stifel
PremiumThe Fly
NervGen Pharma price target raised to C$5 from C$4.50 at Stifel
3M ago
NervGen Pharma Announces Breakthrough Results in Spinal Cord Injury Treatment Trial
PremiumCompany Announcements
NervGen Pharma Announces Breakthrough Results in Spinal Cord Injury Treatment Trial
3M ago
NervGen reports topline data from chronic cohort of Phase 1b/2a trial of NVG-291
PremiumThe Fly
NervGen reports topline data from chronic cohort of Phase 1b/2a trial of NVG-291
3M ago
NervGen Pharma to Present Promising NVG-291 Study Results at ASIA Meeting
PremiumCompany Announcements
NervGen Pharma to Present Promising NVG-291 Study Results at ASIA Meeting
4M ago
NervGen Pharma Awards Stock Options to Directors and Employees
PremiumCompany AnnouncementsNervGen Pharma Awards Stock Options to Directors and Employees
4M ago
NervGen Pharma Reports Q1 2025 Financial Results and Advances NVG-291 Clinical Development
Premium
Company Announcements
NervGen Pharma Reports Q1 2025 Financial Results and Advances NVG-291 Clinical Development
4M ago
NervGen Pharma Secures Shareholder Support at AGM
Premium
Company Announcements
NervGen Pharma Secures Shareholder Support at AGM
4M ago
NervGen Pharma to Present at 2025 Healthcare Investor Conference
PremiumCompany Announcements
NervGen Pharma to Present at 2025 Healthcare Investor Conference
5M ago
NervGen Pharma Updates on Equity Program, Raises Over $1.6 Million
PremiumCompany Announcements
NervGen Pharma Updates on Equity Program, Raises Over $1.6 Million
5M ago
NervGen Pharma Advances SCI Treatment with NVG-291 and NVG-300
PremiumCompany Announcements
NervGen Pharma Advances SCI Treatment with NVG-291 and NVG-300
5M ago
NervGen Pharma Launches Expanded Access for NVG-291
PremiumCompany Announcements
NervGen Pharma Launches Expanded Access for NVG-291
5M ago
NervGen Pharma to Host Virtual Event on Spinal Cord Injury Treatment
PremiumCompany AnnouncementsNervGen Pharma to Host Virtual Event on Spinal Cord Injury Treatment
6M ago
NervGen Pharma Grants 545,000 Stock Options to Employees and Consultants
Premium
Company Announcements
NervGen Pharma Grants 545,000 Stock Options to Employees and Consultants
6M ago
NervGen Pharma to Present at Virtual Life Sciences Investor Forum
Premium
Company Announcements
NervGen Pharma to Present at Virtual Life Sciences Investor Forum
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >